Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volume 26, Issue 7, July 2015, Pages 1333-1340.

Ann Oncol

Department of Medical Oncology, University of Crete, School of Medicine, Heraklion, Greece.

Published: March 2020

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.annonc.2020.01.004	DOI Listing

Publication Analysis

corrigendum versus

versus months

months adjuvant

adjuvant trastuzumab

trastuzumab combination

combination dose-dense

dose-dense chemotherapy

chemotherapy women

women her2-positive

her2-positive breast

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!